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Use of the Glycophorin A Human Muta-
tion Assay to Study Workers Exposed to
Styrene
by Penelope J. E. Compton-Quintana,' Ronald H.
Jensen,2 William L. Bigbee,2 Stephen G. Grant,2
Richard G. Langlois,2 Martyn T. Smith,' and Stephen
M. Rappaport13
The glycophorin A (GPA) assay is a human mutation assay that is potentially useful for large epidemiological studies.
The assay is rapid and requires a minimal amount of blood, which can be stored before analysis. The data presented here
were collected from workers exposed to styrene in a boat manufacturing plant. This study was the first toapply the GPA
assay to an occupationally exposed population. Subjects with a mean styrene exposure of30 ppm had a higher frequen-
cy of GPA N4 variant cells than subjects with mean exposure of 1 ppm, but the subjects differed in respect to smoking
and age distribution. Results indicate that the original l-W-1 version of the assay may not be suitable for studies of small
numbers ofexposed subjects due to variability and artifacts. The newer BR6 version, however, has much lower variability
and shows promise for use in the occupational setting.
Introduction
The glycophorin A (GPA) gene loss mutation assay estimates
genetic damage to humans by measuring the frequency ofGPA-
variant red blood cells in peripheral blood samples (1,2). The
GPA assay has advantages for the epidemiologist over the other
mutation assays currently available, namely, the hprt, HLA-A, and
Hb-S assays (3). TheGPA assay is rapid and simplecompared to
the hprt and HLA-A assays-the results can be obtained within 48
hr, and the assay requires a minimal (< 1 mL) blood sample that
can be stored for up to 2 weeks at refrigerator temperatures. The
GPA assay also presumably detects a wider spectrum of muta-
tional mechanisms than the hprt and Hb-S assays because GPA
variant cells may arise from mutations that involve chromosome-
wide events or chromosomal interactions such as mitotic recom-
bination (2). The latter mechanisms have been found to be in-
volved in the loss of tumor-suppressor genes, as reviewed by
Grant et al. (4).
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There are also disadvantages to the GPA assay from the
epidemiological perspective; the GPA assay requires a specific
blood type (MN) and so can be performed on only about 50% of
all subjects, and, in addition, it measures mutations in bone mar-
row cells only because circulating red blood cells lack a nucleus.
The effect ofexposure must therefore penetrate to bone marrow
to result in a response. Elevated frequencies ofGPA-variant cells
have been found in subjects exposed to ionizing radiation (5,6),
in patients receiving high doses of antineoplastic drugs (7), and
in persons with cancer-prone syndromes (8,9).
This study was undertaken to evaluate the potential utility of
the GPA assay in a low-exposed population more typical of en-
vironmental epidemiology than the high-dose/high-risk popula-
tions, previously studied, using the original l-W-I version ofthe
GPA assay (1) as well as a new and more precise version of the
assay (BR6) developed (2) during the time period of the study.
The data presented here represent the first application oftheGPA
assay to an occupationally exposed population.
Materials and Methods
Determination ofGPA Variant Cell Frequency
The GPA assay was performed essentially as described (1,2).
Briefly, fixed red blood cells obtained from heterozygous (MN)
individuals were reacted with fluorescently labeled monoclonal
antibodies toM andN forms ofGPA. A flow cytometerwas used
to measure fluorescence from each cell. Normal MN cells
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FIGURE 1. (A) Flow-cytometric measurements of-fluorescence from mixture
of MM, MN, and NN cells stained with anti-M and anti-N antibodies. (B)
Results of BR6 assay using I million red blood cells from a low-exposed
styrene worker. Six N4 and nine NN GPA variant cells were found. The
average of five such assays was 5.5 N$ and 7.5 NN variant cells per million
red cells.
fluoresce both red (anti-M antibody) and green (anti-N an-
tibody), and variant cells fluoresce green only; N4 variants
(missing theM form) show the same level ofgreen fluorescence
as normal cells, and NN variants show double the normal green
fluorescence level. These two classes of variants presumably
arise through different mechanisms, gene inactivation and gene
duplication. Data outputs are typically in the form ofhistograms
with green fluorescence on one axis and red on the other, using
counts as a third dimension. Figure IA shows a histogram from
the BR6 assay ofa mixture ofMM, MN, and NN blood cells that
is used to set expectations for fluorescence ofvariant cells. Figure
[B is a histogram of 1 million cells from a worker exposed to a
low level of styrene. As can be seen, variant cells contribute only
a few counts per million MN red cells counted. The variant cell
frequency, averaged over 5 such runs of 1 million cells each from
this worker, was 5.5 N4 variants per million and 7.5 NN variants
per million.
Two versions of the GPA assay were used. The original (1),
known as l-W-1, used a dual-beam flow cytometer with sorter
(DBS). The sorter was necessary because the antibody combina-
tions used frequently generated artifacts, especially NN artifacts,
in the fluorescence histograms, and visual confirmation of
separated variant cells was necessary. However, the sorter itself
introduced additional variability, and the DBS is a complex in-
strument requiring skilled maintenance. Obtaining a new an-
tibody combination allowed the development of a new assay
known as BR6 (2) based on a commercially available single-
beam flow cytometer without a sorter. The BR6 assay shows im-
proved precision, especially for NN variants, and more cells can
be collected per subject, which reduces the variability due to
Poisson distribution of rare events. The lower cost and ease of
operation ofthe countertop, single-beam flow cytometer will aid
in export of this assay to other laboratories.
Study Population
The population studied was a group of workers in a boat-
manufacturing plant exposed to styrene during hand lamination
of the boat hulls. Other plant employees with low styrene ex-
posures, such as maintenance workers, were used as controls.
Styrene oxide is a carcinogen in rodents and styrene and styrene
oxide are mutagenic in human cells in Witro. Cytogenetic studies
ofpeople occupationally exposed to styrene vapor have found in-
creases in chromosomal aberrations, micronuclei, single-strand
DNA breaks, and unscheduled DNA synthesis in peripheral
lymphocytes [reviewed in Bond (10), Barale (11), and Maki-
Paakkanen et al. (12)].
This study was part of a larger study at University of Cali-
fornia at Berkeley that examined multiple end points of styrene
exposure: air levels, exhaled air levels, and blood levels of
styrene; adducts of styrene oxide to hemoglobin, albumin, and
DNA; glutathione S-transferase enzyme levels in blood; micro-
nuclei frequencies and sister chromatid exchange frequencies in
lymphocytes; and GPA variant frequencies in red blood cells
(13,14). This was a longitudinal study design in which air and ex-
haled air levels were determined during eight survey visits over
the course of 18 months, with blood samples being obtained on
five of these visits. All workers were administered a confiden-
tial questionnaire to determine past exposures that could cause
genotoxic damage or could interfere with the assays used.
Results
Styrene Exposure of Subjects
Overall, 61 workers participated in the study, with 37 ofthem
having the MN blood type required for use of the GPA assay.
Workers were continuously recruited to the study between
surveys 1 and 5 to reach the maximum of 37 MN subjects, and
enrollment declined in surveys 6, 7, and 8 due tojob terminations,
absences at the time of visit, or transfers to another shift. Due to
the difficulty ofobtaining subjects for the study, all workers will-
ing to participate were enrolled regardless of smoking status.
However, enrolled workers had to have worked in the plant for
at least 1 year. Blood samples were drawn on surveys 1, 3, 5, 7,
and 8. Survey 8 was made specifically to apply the then-new BR6
assay to subjects in the styrene study.
Job classification was found not to be a reliable guide to ex-
posure classification. Theworkers who were originally enrolled
in the study as controls on the basis that they were employed
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FIGURE 2. Mean and SD of styrene concentration in breathing zone, meas-
ured for each of 30 workers and averaged over the study period. Workers were
assigned to exposure groups as shown. In addition to the workers shown in
this figure, there were six additional workers in exposure category 0 and one
additional worker in category I for whom no air concentrations of styrene
were measured. All additional workers were assumed to have been exposed
to less than 10 mg/m3 of styrene because all worked in outbuildings.
in the plant but did not work with styrene all proved to have low
but measurable exposure to styrene, from 0.25 to 3.5 ppm (1-15
mg/m3). However, time-weighted average exposures to styrene
showed suprisingly little seasonal variation, so that workers
could be grouped into exposure categories based on their overall
mean exposure. The workers were divided into exposure cate-
gories, as shown in Figure 2. Exposure category 4 had average
exposures of 170 mg/m3 (40 ppm), and exposure category 3
averaged 55 mg/m3 (13 ppm), whereas categories 4 and 3 com-
bined averaged 132 mg/m3 (32 ppm). Exposure category 0 was
made up of persons who had never worked with styrene and
category I ofthose not currently working with styrene but who
had previously worked with styrene. The distinction between
category 0 and category 1 was made because functionally im-
mortal stem cells in the bone marrow give rise to the red blood
cells measured, so that exposure to styrene in the past could
cause a current elevation in variant frequencies if styrene had
given rise to GPA-mutated stem cells. The mean exposure of
categories 1 and 0 combined was 1.2 ppm (5 mg/m3).
Styrene Exposure and GPA Variant Frequencies
To study the effect of styrene on GPA variant frequencies, com-
parisons were made of variant frequency (per million red cells)
of workers in exposure category 4 (10 workers) versus category
0 (12 workers) and categories 4 and 3 combined (15 workers) ver-
sus categories I and 0 combined (15 workers). While categories
4 and 0 differ most in styrene exposure, differences in variant fre-
quency are harder to detect with significance because they have
smaller numbers of workers than the combined categories. In ad-
dition, comparisons made using exposure category 4 are the
most compromised from the epidemiological viewpoint, because
this category contains a higher proportion of older women and
smokers than any other category. The GPA variant frequencies
measured in this study did not fit a normal or log-normal
distribution on statistical fit tests. The median values were used
in all analyses so as to minimize the effects of outlier-measured
variant frequencies. Due to technical difficulties encountered
3
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FIGURE 3. Measurements using the BR6 assay on blood collected during final
survey. (A) N4' and (B) NN GPA variant frequency, compared by worker ex-
posure group. The data are presented using a boxplot format, a nonparametric
presentation where the box encloses the middle 50% of the data and the me-
dian is shown as a line. The shaded areas represent approximately the 95%
confidence interval of the median determined for that data set; (*) and (o)
represent outliers.
with using the original l-W-l assay for the measurement ofNN
variants, specifically with the occurrence of artifacts that in-
crease measured frequencies ofNN variants, the decision was
made that the measurements ofNN variant frequencies using the
I-W-1 assay should not be used. This conclusion was also reached
by Kyoizumi et al. (15). The median values of N4 variant fre-
quency (per million) measured using the 1-W-1 assay were:
categories 4+3, median = 10.3 compared to categories 1+0, me-
dian = 6.9 (p = 0.028) (all probabilities given are Mann-
Whitney). Category 4 had a median N4 of 10.8 per million, as
compared to 8.4 for category 0 (p = 0.088).
Two measurement runs were made on the blood from each
worker in each survey, and examination of the N4 variant fre-
quencies suggested that the results from the second run showed
a higher variability than those from the first run. The NcI me-
dians of categories 4+3 compared to categories 1+0 using data
from the first run only are 9.64 versus 4.4, withp = 0.0164. Com-
paring category 4 with category 0 the medians are 8.5 versus 4.9,
withp = 0.060.
Survey 8 was made to apply the new BR6 assay being de-
veloped at that time to subjects in this study. Unfortunately, it was
only possible to collect blood from 9 workers in categories
4+3 (down from 15 in earlier surveys). Figure 3 shows GPA me-
dian frequencies obtained using the BR6 assay. For N4 variant
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frequencies, categories 4+3 have a median of 6.7 versus 4.7 for
categories 1+0, withp = 0.087, whereas category 4 has a median
of 8.0 versus 3.5 for category 0, with p = 0.055. Again, these
results suggest an increase in N4 variant frequency in the more
highly exposed categories, but because the categories are not
directly comparable with respect to smoking and other factors
the effect could be due to exposures other than to styrene. The
results do not suggest any increase in the frequency of NN
variants with increasing styrene exposure.
Effect of Possible Confounding Factors
A clear separation ofthe effects ofstyrene and smoking is not
possible because a greaterproportion ofthe smokerswereexposed
to styrene: 50% ofthe smokers were exposed compared to 25%
of nonsmokers. Comparing factor by factor, there is no indica-
tion of a GPA variant frequency increase with smoking, nor with
a history of X-ray exposure. An effect of age (< 40 or >40
years) is suggested in theNN variant frequency, both for all ex-
posure categories (p = 0.089) and for exposure categories 1+0
(p = 0.036). For the NN variants, females appear to have a
greater variant frequency than males, both for all exposure
categories combined (p = 0.096) and in exposure categories 1+0
(p = 0.0188). This effect is probably due to the greater propor-
tion of subjects over 40 years old among females than among
males. Age therefore seems to be the major confounder forGPA
NN variant frequencies measured in the GPA assay (Compton-
Quintana et al., manuscript in preparation.)
Performance of the GPA Assay
One great improvement that has resulted from the development
of the BR6 version of the GPA assay is the reduction of the
variance in measurements ofGPA variant frequency. The coef-
ficient of variation (CV) has been reported by Langlois et al.(2),
using fresh blood samples from 17 selected laboratory normal
donors under the most favorable laboratory conditions, to be 64%
for NcI and 132% for NN variant frequencies in the I-W-l assay,
and 30% and 19% for N4 and NN, respectively, in the BR6 assay.
The results in the occupational setting reported here show a con-
siderably higher variance using the 1-W-1 assay. For subjects in
exposure categories 1 and 0, the CV measured using the 1-W-1 as-
say was 135% for N4 variant frequencies and 137% forNN var-
iant frequencies. These values for the CV represent what might
be expected from the I-W-1 GPA assay ifblood is collected in the
the occupational setting and shipped for analysis under the con-
ditions of this study. Using the BR6 assay, the CV was 27% for
N4 variant frequencies and 24% for NN variant frequencies.
Because in this study multiple measurements were made per
workers, the effect of the variance ofthe 1-W-1 assay was mini-
mized and the power of the l-W-I assay was increased to a level
similar to that of a one-time measurement using the BR6 assay.
This illustrates the importance of longitudinal studies.
Discussion
One of the strengths of this study design is the longitudinal
characterization of the styrene exposure of the workers, reduc-
ing the possibility that workers are wrongly classified into
styrene exposure categories and also increasing the power of the
study through increasing the number of blood samples per
worker. However, the small number of subjects, the presence of
possible confounding factors such as smoking, and the low con-
centrations ofstyrene to which the exposed workers were in fact
exposed all tended to decrease the capability ofthe detect an ef-
fect, if present, of styrene.
The frequency ofGPA N4I type variants but not NN variants
is increased in workers more highly exposed to styrene, although
the level of statistical significance is not compelling. The finding,
if real, that the genotoxic effect of styrene apparently increases
N4l-type GPA variants to a greater extent than than NN-type
variants accords with the finding that styrene oxide and styrene
+S9 are classified as mutagens in the Ames test and other assays.
These results should be confirmed with a larger number of sub-
jects in exposure categories that are better matched for age,
gender, and smoking, and such a study is, in fact, being carried
out (Bigbee et al., manuscript in preparation).
The original 1-W-1 version of the assay has a high variability,
which would make detection of a small effect difficult. Many of
the sources of variability in the GPA assay, however, have been
reduced or eliminated in the newer BR6 assay. The BR6 assay
therefore holds much more promise for the successful applica-
tion of the GPA assay to occupationally or environmentally ex-
posed populations. Data from this study suggest that age, and
possibly sex, are confounders in the GPA assay and should be
carefully controlled in future studies. GPA varant frequency may
also be affected by individual susceptibility to mutation. Data
from persons given chemotherapy (7) demonstrated that patients
receiving a direct-acting chemotherapeutic agent had a more
uniform increase in GPA variant frequency than those receiving
an agent requiring metabolic activation, a process that is known
to vary between individuals.
In summary, theGPA assay has been shown to have both unique
advantages as well as disadvantages. It is rapid and requires a min-
mal amountofblood for analysis. However, it is clear that more
characterization needs to be made of the sources of variability,
including those present in the assay itself, those arising from
natural differences in MN variant frequency in the general
population, and those associated with confounders of the assay,
before the GPA assay can be applied routinely for biological
monitoring studies. Until such information is obtained, the most
productive plan may be to obtain a pre- and post-exposure sam-
ple, to the extent feasible in the occupational or environmental
setting, and use each subject as his or her own control.
This manuscript was presented as a poster at the Conference on Biomonitor-
ing and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona, Hawaii, 26
October-I November 1991.
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